Drugs that contain Dexamethasone
1. List of Dextenza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254267 | OCULAR THERAPEUTIX | Composite hydrogel drug delivery systems |
Sep, 2024
(1 year, 7 months from now) | |
| US8563027 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
Feb, 2030
(7 years from now) | |
| US8409606 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
May, 2030
(7 years from now) | |
| US11458041 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Nov, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Oct 7, 2024 |
Market Authorisation Date: 30 November, 2018
Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain following ophthalmic surgery
Dosage: INSERT;OPHTHALMIC
2. List of Dexycu Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7560120 | EYEPOINT PHARMS | Vehicles for delivery of biologically active substances |
Sep, 2022
(4 months ago) | |
| US6960346 | EYEPOINT PHARMS | Vehicles for delivery of biologically active substances |
Jul, 2023
(4 months from now) | |
| US10799642 | EYEPOINT PHARMS | Dose guides for injection syringe |
May, 2032
(9 years from now) | |
| US10028965 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(11 years from now) | |
| US10159683 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(11 years from now) | |
| US10022502 | EYEPOINT PHARMS | Dose guides for injection syringe |
Jun, 2034
(11 years from now) | |
| US11097061 | EYEPOINT PHARMS | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
Jun, 2039
(16 years from now) | |
Market Authorisation Date: 09 February, 2018
Treatment: Treatment of postoperative inflammation; A method of loading medication into a syringe and delivering the medication to a treatment site
Dosage: SUSPENSION;INTRAOCULAR
3. List of Hemady drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537585 | DEXCEL PHARMA | Compositions comprising dexamethasone |
Dec, 2037
(14 years from now) | |
| US11304961 | DEXCEL PHARMA | Compositions comprising dexamethasone |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 3, 2026 |
Market Authorisation Date: 03 October, 2019
Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product
Dosage: TABLET;ORAL
4. List of Ozurdex drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8506987 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(25 days ago) | |
| US8034366 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(25 days ago) | |
| US9192511 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(25 days ago) | |
| US10076526 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(25 days ago) | |
| US8034370 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(25 days ago) | |
| US10702539 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(25 days ago) | |
| US6899717 | ALLERGAN | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(8 months from now) | |
Market Authorisation Date: 17 June, 2009
Treatment: Treatment of macular edema; Treatment of uveitis; Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); Treatment of non-infectious uveitis affecting the posterior segment of the eye; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex
Dosage: IMPLANT;INTRAVITREAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic